
March 31 (Reuters) - Carisma Therapeutics Inc CARM.O:
CARISMA THERAPEUTICS PROVIDES CORPORATE UPDATES
CARISMA THERAPEUTICS INC: TO EXPLORE STRATEGIC ALTERNATIVES TO ADVANCE LIVER FIBROSIS AND ONCOLOGY ASSETS AND REDUCE OPERATIONAL CASH BURN
CARISMA THERAPEUTICS INC: HAS REDUCED ITS WORKFORCE, RETAINING ONLY THOSE EMPLOYEES DEEMED ESSENTIAL TO PURSUE STRATEGIC ALTERNATIVES
CARISMA THERAPEUTICS INC: ESTIMATES THAT IT HAS CASH AND CASH EQUIVALENTS SUFFICIENT TO FUND ITS OPERATIONS INTO SECOND HALF OF 2025
CARISMA : MAY ENGAGE EXTERNAL ADVISORS TO SUPPORT EVALUATION OF STRATEGIC ALTERNATIVES, PREPARE FOR POTENTIAL WIND-DOWN OF OPERATIONS, IF NECESSARY
CARISMA THERAPEUTICS INC: HAS REDUCED OPERATIONS TO CORE FUNCTIONS NECESSARY TO SUPPORT THIS STRATEGIC REVIEW
CARISMA THERAPEUTICS INC: HAS PAUSED ALL RESEARCH AND DEVELOPMENT ACTIVITIES AT THIS TIME, PENDING OUTCOME OF REVIEW